Literature DB >> 12404881

Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations.

Luigi Allegra1, Monica Dal Sasso, Cinzia Bovio, Carola Massoni, Elena Fonti, Pier Carlo Braga.   

Abstract

Reactive oxygen species released by activated polymorphonuclear leukocytes as an expression of their defensive function are considered to be a major source of the cytotoxic oxidant stress, that triggers a self-sustaining phlogogenic loop in the respiratory system. N-Acetylcysteine (CAS 616-91-1, NAC), a known mucolytic drug, possesses also antioxidant properties, but it undergoes a rapid and extensive first-pass metabolism resulting in low tissue availability. Thus to further improve the NAC bioavailability a single oral administration of 1200 mg NAC has been recently proposed. This study has been performed to investigate in vitro by means of luminol amplified chemiluminescence the ability of the concentration of 35 mumol/l NAC available after single oral administration of 1200 NAC to interfere with human neutrophil oxidative burst evoked by both corpuscolate and soluble stimulants, in comparison with 16 mumol/l NAC, the serum concentration obtainable after single oral administration of 600 mg NAC. At concentrations of 16 and 35 mumol/l, NAC significantly reduced in a concentration-dependent manner the activation of polymorphonuclear neutrophils (PMNs) oxidative bursts induced by all of the stimulants (C. albicans, formyl-methionyl-leucyl-phenylalanine (fMLP), phorbol myristate acetate (PMA)). This effect was also present in cell-free systems, thus confirming the scavenger activity of these two concentrations of NAC. The fact that no effects were seen on PMN phagocytosis and bacterial killing indicates that NAC has no negative influence on other PMN functions such as antimicrobial activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404881     DOI: 10.1055/s-0031-1299949

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

Review 1.  N-acetylcysteine -- passe-partout or much ado about nothing?

Authors:  Mirja-Liisa Aitio
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

2.  Effect of alpha-tocopherol, N-acetylcysteine and omeprazole on esophageal adenocarcinoma formation in a rat surgical model.

Authors:  Jing Hao; Bin Zhang; Ba Liu; Maojung Lee; Xingpei Hao; Kenneth R Reuhl; Xiaoxin Chen; Chung S Yang
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

Review 3.  Possible Treatment Approaches of Sulfur Mustard-Induced Lung Disorders, Experimental and Clinical Evidence, an Updated Review.

Authors:  Mohammad Reza Khazdair; Mohammad Hossein Boskabady
Journal:  Front Med (Lausanne)       Date:  2022-04-29

4.  Influence of the protein kinase C activator phorbol myristate acetate on the intracellular activity of antibiotics against hemin- and menadione-auxotrophic small-colony variant mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells.

Authors:  Laetitia G Garcia; Sandrine Lemaire; Barbara C Kahl; Karsten Becker; Richard A Proctor; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

5.  Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.

Authors:  Mario Cazzola; Luigino Calzetta; Francesco Facciolo; Paola Rogliani; Maria Gabriella Matera
Journal:  Respir Res       Date:  2017-01-24

6.  The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.

Authors:  Jaclyn Sceneay; Mira C P Liu; Anna Chen; Christina S F Wong; David D L Bowtell; Andreas Möller
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

Review 7.  N-Acetylcysteine to Combat COVID-19: An Evidence Review.

Authors:  Zhongcheng Shi; Carlos A Puyo
Journal:  Ther Clin Risk Manag       Date:  2020-11-02       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.